Melanoma

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
Doreen Lau, Mary A McLean, Andrew N Priest, Andrew B Gill, Francis Scott, Ilse Patterson, Bruno Carmo, Frank Riemer, Joshua D Kaggie, Amy Frary, Doreen Milne, Catherine Booth, Arthur Lewis, Michal Sulikowski, Lee Brown, Jean-Martin Lapointe, Luigi Aloj, Martin J Graves, Kevin M Brindle, Pippa G Corrie, Ferdia A Gallagher

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003125; DOI: 10.1136/jitc-2021-003125
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
Pankti Reid, David FL Liew, Rajshi Akruwala, Anne R Bass, Karmela K Chan

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e003260; DOI: 10.1136/jitc-2021-003260
High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4⁺ and CD8⁺ neoantigen-specific T cells to promote antitumor immunity
Rosmely Hernandez, Kathryn M LaPorte, Sunnie Hsiung, Alicia Santos Savio, Thomas R Malek

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002865; DOI: 10.1136/jitc-2021-002865
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandalá, James Larkin, Paolo A Ascierto, Michele Del Vecchio, Helen Gogas, C Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De La Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil I Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey Weber

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003188; DOI: 10.1136/jitc-2021-003188
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, Walter C Olson, Nolan A Wages, Kimberly A Chianese-Bullock, Mark Smolkin, Nikole Varhegyi, Elizabeth Gaughan, Kelly T Smith, Kathleen Haden, Emily H Hall, Sacha Gnjatic, Patrick Hwu, Craig L Slingluff

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003220; DOI: 10.1136/jitc-2021-003220
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
Yong-Chen Lu, Zhili Zheng, Frank J Lowery, Jared J Gartner, Todd D Prickett, Paul F Robbins, Steven A Rosenberg

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002595; DOI: 10.1136/jitc-2021-002595
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Yana G Najjar

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002820; DOI: 10.1136/jitc-2021-002820
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
Katharina Filipski, Michael Scherer, Kim N. Zeiner, Andreas Bucher, Johannes Kleemann, Philipp Jurmeister, Tabea I. Hartung, Markus Meissner, Karl H. Plate, Tim R. Fenton, Jörn Walter, Sascha Tierling, Bastian Schilling, Pia S. Zeiner, Patrick N. Harter

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002226; DOI: 10.1136/jitc-2020-002226
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
Benjamin Switzer, John Haanen, Paul C Lorigan, Igor Puzanov, Samra Turajlic

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002835; DOI: 10.1136/jitc-2021-002835
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Takashi Nakamura, Takanori Sato, Rikito Endo, Shun Sasaki, Naomichi Takahashi, Yusuke Sato, Mamoru Hyodo, Yoshihiro Hayakawa, Hideyoshi Harashima

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002852; DOI: 10.1136/jitc-2021-002852

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages